ReviewJournal of diabetes science and technology2026
Inpatient Use of Automated Insulin Delivery Systems.
Review in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAutomated insulin delivery (AID) systems have improved outpatient glycemic control, reduced hypoglycemia, and enhanced quality of life for many people with diabetes. Interest is growing in translating these systems to inpatient care, where conventional insulin regimens are frequently associated with glycemic excursions and highly variable insulin requirements.
methodsWe conducted a narrative review of peer-reviewed studies evaluating inpatient use of AID systems, including both hospital-initiated AID and continuation of personal outpatient AID devices during hospitalization, across medical and surgical populations.
resultsAs outpatient adoption of AID systems increases, hospital clinicians are encountering patients using these technologies more frequently during admission. Available studies of both hospital-initiated AID and continued personal AID use during hospitalization suggest feasibility and safety, with improvements in time in range and no clear increase in hypoglycemia, although large-scale data remain limited. Broader implementation is constrained by important operational and regulatory barriers, including limited electronic health record integration, lack of device interoperability, regulatory clearance, and the absence of standardized institutional policies.
conclusionAs inpatient exposure to AID systems continues to expand, hospitals must develop infrastructure and operational policies to support safe use of personal devices and to evaluate hospital-initiated AID for patients with difficult-to-manage hyperglycemia. This review summarizes current evidence and highlights key challenges to integrating AID systems into routine inpatient diabetes care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.